Commodore Capital LP's Schedule 13G Filing for Palisade Bio, Inc.

Commodore Capital LP, along with Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz, filed a Schedule 13G with the SEC on October 8, 2025, disclosing their beneficial ownership of Palisade Bio, Inc. The filing indicates that Commodore Capital LP, as the investment manager to Commodore Capital Master LP, may be deemed to beneficially own an aggregate of 9,690,665 shares of Common Stock of Palisade Bio, Inc. This includes 9,332,443 shares of Common Stock and 358,222 shares of Common Stock underlying a pre-funded warrant, subject to a beneficial ownership limitation of 9.99%. The filing also notes that Michael Kramarz and Robert Egen Atkinson, as managing partners of Commodore Capital LP, exercise investment discretion over these securities. The ownership percentages are based on 96,645,431 shares of the Issuer's Common Stock outstanding as of October 1, 2025, plus 358,222 shares of Common Stock which the Filers may acquire upon the exercise of the pre-funded warrant, subject to the Beneficial Ownership Limitation.